Cholecystokinin Octapeptide Ammonium: Mechanisms, Evidence, and Lab Integration

Executive Summary: Cholecystokinin octapeptide ammonium (SKU C8717) is a synthetic, sulfated peptide and a potent agonist of CCK1R and CCK2R receptors, with verified roles in modulating neuronal plasticity, anxiety-like behaviors, and apoptosis in vitro and in vivo (APExBIO product page). The biological effects of CCK-8 ammonium are concentration-dependent, with optimal in vitro ranges between 0.01–1 μmol/L for apoptosis inhibition and immune response modulation (Wen et al., 2014). The sulfation state is essential for activity; desulfated forms lack key functions such as atrial natriuretic peptide secretion. Robust evidence confirms its ability to restore morphine-impaired hippocampal long-term potentiation (LTP) via CCK2R pathways. This article compiles mechanistic insights, benchmark results, and workflow guidance for CCK-8 ammonium in laboratory practice.

Biological Rationale

Cholecystokinin (CCK) is a pleiotropic peptide hormone with major roles in the central and peripheral nervous systems. The octapeptide, CCK-8, is the predominant active form in the CNS. CCK-8 exists mainly in a sulfated state (CCK-8s), which is necessary for high-affinity receptor binding and functional activity (APExBIO). The ammonium salt form, cholecystokinin octapeptide ammonium (CAS No. 70706-98-8), is highly soluble in DMSO and is suitable for precise laboratory applications.

CCK-8 ammonium interacts with G protein-coupled receptors CCK1R and CCK2R, triggering intracellular signaling cascades that influence apoptosis, immune responses, neurobehavioral functions, and hormone release. These pathways include β-arrestin 2, p38 MAPK, Akt, NOX4, PGC-1α, and PPARα/PPARγ, representing a broad regulatory spectrum.

Mechanism of Action of Cholecystokinin Octapeptide Ammonium

CCK-8 ammonium acts as an agonist at CCK1R (peripheral) and CCK2R (central) receptors. Upon binding, CCK-8s initiates downstream signaling via:

• β-arrestin 2 recruitment: Facilitates receptor desensitization and internalization.
• p38 MAPK and Akt activation: Promotes cell survival, proliferation, and anti-apoptotic effects.
• NOX4 and PGC-1α: Modulates oxidative stress and cellular metabolism.
• PPARα/γ pathways: Regulates lipid metabolism and inflammatory responses.

The sulfation of the tyrosine residue in CCK-8 is critical for high-affinity receptor interaction and for certain biological effects, such as induction of atrial natriuretic peptide (ANP) secretion and anti-analgesic activity. Desulfated CCK-8 is functionally inactive in these contexts (APExBIO).

Evidence & Benchmarks

• CCK-8 (1 μg, i.c.v.) restores morphine-impaired hippocampal LTP in rats via CCK2R activation (Wen et al., 2014).
• In vitro, CCK-8 ammonium at 0.1 μmol/L inhibits apoptosis in neuronal cells by modulating caspase signaling (Wen et al., 2014).
• CCK-8 ammonium induces anxiety-like behaviors in zebrafish models at doses >0.05 μmol/L (APExBIO).
• The sulfated form is required for ANP secretion; desulfated CCK-8 fails to induce secretion and does not counteract morphine analgesia (APExBIO).
• CCK-8 attenuates morphine withdrawal-induced anxiety and restores hippocampal spine density in vivo (rat, 1 μg, i.c.v.) (Wen et al., 2014).

This article extends scenario-based workflow discussions in Enhancing Assay Reproducibility with Cholecystokinin Octapeptide, providing mechanistic detail and an updated regulatory context. For practical assay integration, see also Cholecystokinin Octapeptide Ammonium (SKU C8717): Practical Guide, which focuses on troubleshooting and protocol optimization. The present synthesis offers a more granular evidence audit and clarifies boundary conditions for CCK-8 ammonium use.

Applications, Limits & Misconceptions

Cholecystokinin octapeptide ammonium is validated for:

• Inhibition of apoptosis in neuronal and immune cell models, typically at 0.01–1 μmol/L in vitro.
• Modulation of immune responses through PPAR-related pathways.
• Induction of anxiety-like behaviors in zebrafish and rodent models, context-dependent.
• Restoration of synaptic plasticity post-morphine exposure in rat hippocampus.
• Promotion of atrial natriuretic peptide secretion (only active in sulfated form).

Common Pitfalls or Misconceptions

• Desulfated CCK-8 is inactive: Only the sulfated form (CCK-8s) is functionally active at CCK receptors and in neuroendocrine assays (APExBIO).
• Overdosing may induce paradoxical effects: High in vivo doses (>1 μg, i.c.v. in rats) can induce anxiety-like behavior rather than anxiolysis (Wen et al., 2014).
• Long-term storage of solutions is not recommended: Prepare fresh aliquots; storage at -20°C under nitrogen is required for the lyophilized product.
• Receptor subtype selectivity matters: CCK2R mediates most central nervous system effects; CCK1R is more peripheral.
• CCK-8 does not substitute for endogenous endorphin release control except in defined models.

Workflow Integration & Parameters

For optimal results, reconstitute cholecystokinin octapeptide ammonium in DMSO to a stock concentration suitable for planned dilutions. Use immediately after preparation; avoid freeze-thaw cycles. Recommended in vitro concentrations range from 0.01–1 μmol/L for apoptosis or immune assays. For in vivo rat studies, microinjection doses of 0.1–1 μg (i.c.v.) have demonstrated efficacy in modulating hippocampal LTP and behavioral outputs (Wen et al., 2014).

APExBIO, as the originating company for SKU C8717, specifies dry storage at -20°C under nitrogen and protection from light. For stepwise scenario-driven guidance, refer to Cholecystokinin Octapeptide Ammonium: Applied Workflows, which this article updates with new benchmarks and mechanistic clarity.

Conclusion & Outlook

Cholecystokinin octapeptide ammonium (CCK-8 ammonium) is a rigorously characterized CCK1R/CCK2R agonist with broad utility in neuroscience and immunology research. Its biological actions are highly context-dependent, requiring precise control of sulfation state, concentration, and receptor targeting. Peer-reviewed evidence supports its use in apoptosis inhibition, immune modulation, anxiety modeling, and restoration of synaptic plasticity. Researchers are advised to follow best-practice protocols for storage, handling, and dosing to ensure reproducibility. Future studies may further delineate receptor subtype effects and expand translational applications.

To order or access further product specifications, visit the Cholecystokinin octapeptide ammonium product page.